Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.
Derm In The News: September 17-23
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
CeraVe Partners With George Washington University to Expand Residency Training Program
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Combination Treatments in HS Require Further Review
Frontline Forum Part 4: Improving Basal Cell Carcinoma Management